 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
NIC5-15
|
|
Therapeutic Applications:
|
mild to moderate Alzheimer's disease
|
|
Therapy Types:
|
small molecule
|
|
Mechanisms:
|
NIC5-15 is a naturally occurring anti-diabetic agent with insulin-sensitizing properties. It has also been shown to act as a gamma-secretase inhibitor that spares Notch.
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Phase II/IIa/IIb
|
|
Primary Medical Role:
|
Administration of NIC5-15 for 6 months decreased Aβ40 and
Aβ42 levels in the cerebral cortex and hippocampus of
insulin resistant Tg2576 mice. Reduced Aβ levels were due to
a reduction in γ-secretase activity. Notch-1 levels were
unaffected. In addition to improving Aβ levels, NIC5-15 was
reported to improve cognitive functioning in Tg2576 mice at
12 months of age (Wang et al., 2005).
|
|
Companies:
|
Humanetics Pharmaceuticals
|
|
Notes:
|
According to clinicaltrials.gov this trial is complete. No
study results are posted. NIC5-15 trial.
This entry was updated August 13, 2012.
|
Wang J., Ho L., Passinetti G.M. The Development of NIC5-15,
a natural anti-diabetic agent, in the treatment of
Alzheimer's disease. Alzheimers Dement. (2005) 1 (Suppl. 1) 62. No abstract available
|
|
|
|
|
Home
